cephalosporin c has been researched along with aztreonam in 201 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (23.38) | 18.7374 |
| 1990's | 56 (27.86) | 18.2507 |
| 2000's | 42 (20.90) | 29.6817 |
| 2010's | 41 (20.40) | 24.3611 |
| 2020's | 15 (7.46) | 2.80 |
| Authors | Studies |
|---|---|
| Hanberger, H | 1 |
| Canu, L; Casula, G; Deriu, IP; Scintu, F | 1 |
| Hannecart-Pokorni, E; Nulens, E; Nyssen, HJ; Vanhoof, R | 1 |
| Bailey, EM; Lamp, KC; McGrath, BJ; Rybak, MJ | 1 |
| Blake, J; Cassiano-Clough, L; Cosand, WL; Cunningham, MD; Darveau, RP; Maloney, G; Seachord, CL | 1 |
| Baquero, F; Canton, R; Gomez-Alferez, A; Loza, E; Martinez-Beltran, J | 1 |
| Bush, K; Dougherty, TJ; Gougoutas, JZ; Malley, MF; Ohringer, S; Singer, SB; Sowek, JA | 1 |
| Briedigkeit, H; Halle, E | 1 |
| Hara, T; Inouye, S; Iwamatsu, K; Kawaharajo, K; Komiya, I; Matsumoto, T; Miyata, A; Orikasa, Y; Shibahara, S; Tamura, A | 1 |
| Charak, BS; Louie, R; Malloy, B; Mazumder, A; Twomey, P | 1 |
| Ben Yaghlane Bouslama, H; Labia, R; Sirot, D; Vu Thien, H | 1 |
| Nemoto, M; Saitoh, K; Sakurai, Y; Sawai, T; Yamaguchi, A; Yoshida, Y | 1 |
| Hara, T; Inouye, S; Iwamatsu, K; Ogino, H; Okamoto, R; Orikasa, Y; Yoshida, T | 1 |
| Butler, K; Gress, J; Lecciones, J; Lee, J; Marshall, D; Pizzo, PA; Roilides, E; Rubin, M; Walsh, T; Weinberger, M | 1 |
| Pizzo, PA; Rubin, M | 1 |
| Hubrechts, JM; Nulens, E; Nyssen, HJ; Roebben, E; Vanhoof, R | 1 |
| Adkinson, NF | 1 |
| Abruzzo, GK; Fromtling, RA; Gadebusch, HH; Gill, C; Ponticas, S; Shungu, DL; Valiant, ME; Weissberger, BA | 1 |
| Adkinson, NF; Saxon, A; Swabb, EA | 1 |
| McCracken, GH; Mustafa, MM | 1 |
| Saxon, A | 2 |
| Brickley, X; Duval, J; Legrand, P; Orsoni, A; Soussy, CJ | 1 |
| Boelaert, J; Gordts, B; Lambert, A; Van Landuyt, HW | 1 |
| Daimon, Y | 1 |
| Arlet, G; Buré, A; Jarlier, V; Legrand, P; Paul, G; Philippon, A | 1 |
| Butzler, JP; Coignau, H; De Mol, P; Ghysels, G; Goossens, H; Grados, O; Innocent, H; Levy, J | 1 |
| Perronne, C; Vildé, JL | 1 |
| Akiyama, Y; Hara, K; Kato, Y; Sato, M; Tajima, T; Takizawa, K | 1 |
| Bakken, JS; Clark, RB; Hori, M; Sanders, CC | 1 |
| Amicosante, G; Frère, JM; Galleni, M | 1 |
| Adelman, DC; Beall, GN; Rohr, AS; Saxon, A | 1 |
| Bosso, JA; Marble, DA; Townsend, RJ | 1 |
| Principi, N | 1 |
| Roselle, GA | 1 |
| Duff, P | 1 |
| Barriere, SL | 1 |
| Chin, NX; Neu, HC | 1 |
| Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN | 1 |
| Gilbert, K; Tomasz, A; Tuomanen, E | 1 |
| Neu, HC | 2 |
| Birckel, P; Jehl, F; Monteil, H | 1 |
| Borobio, V; Garcia-Iglesias, MC; Pascual, A; Perea, EJ | 1 |
| Houben, AW; Stobberingh, E; van Boven, CP | 1 |
| Noriega, AR; Otero, JR; Palenque, E | 1 |
| Crassaris, LG; Delidou, K; Paradelis, AG; Stavrakis, AO | 1 |
| Kayser, FH; Novak, J; Strässle, A | 1 |
| Bergeron, MG; Lavoie, GY | 1 |
| Starr, SE | 1 |
| Rouan, MC | 1 |
| Andrew, JH; Dixson, S | 1 |
| Gruninger, RP; Khan, MY; Nelson, SM; Obaid, SR | 1 |
| Aber, RC; Appelbaum, PC; Pankuch, GA; Tamim, J | 1 |
| LeBel, M; Lewis, GP; Paone, RP | 1 |
| Alford, RH; Brown, TH | 1 |
| McColm, AA; Ryan, DM | 1 |
| Elliott, TS; Greenwood, D | 1 |
| Le Noc, D; Le Noc, P; Robert, J | 1 |
| Butzler, JP; De Mol, P; Ghysels, G; Goossens, H; Grados, O; Vanhoof, R | 1 |
| Drutz, DJ; Jorgensen, JH; Strandberg, DA | 1 |
| Labthavikul, P; Neu, HC | 1 |
| Losert-Brüggner, B; Shah, PM; Stille, W | 1 |
| Bodey, GP; Fainstein, V; Weaver, S | 1 |
| Cobbs, CG; Ennis, DM | 1 |
| Luzzaro, F; Pagani, L; Porta, F; Romero, E | 1 |
| Farid, Z; Girgis, NI; Hammad, O; Sultan, Y | 1 |
| Baquero, F; Cantón, R; García de Lomas, J; Gimeno, C; Liñares, J; Martínez-Beltrán, J; Tubau, F | 1 |
| Courvalin, P; Fonzé, E; Frère, JM; Goussard, S; Lamotte-Brasseur, J; Raquet, X | 1 |
| Chong, Y; Kwon, OH; Lee, K | 1 |
| Arlet, G; Fournier, G; Lagrange, PH; Philippon, A; Rouveau, M | 1 |
| Bello, H; Dominguez, M; Garcia, A; Gonzalez, G; Mella, S; Zemelman, R | 1 |
| Greenfield, RA | 1 |
| Freifeld, AG | 1 |
| Gourkou, A; Hatzoudis, G; Legakis, NJ; Pitt, TL; Tzelepi, E; Tzouvelekis, LS; Vatopoulos, AC | 1 |
| Araki, H; Hayashi, T; Kitayama, R; Minami, S; Ochiai, H; Watanabe, Y | 1 |
| Glupczynski, Y; Verbist, L | 1 |
| Babálová, M; Krălíková, K; Krcméry, V; Kubonová, K | 1 |
| Domínguez Herrera, JM; Hernández Guisado, JM; Infante Cossio, P; Jiménez Mejías, ME | 1 |
| Dufort, G; Olivé, T; Ortega, JJ; Ventura, C | 1 |
| Cantu, C; Huang, W; Palzkill, T | 1 |
| Deguchi, K; Fukayama, S; Ishihara, R; Koguchi, M; Oda, S; Suzuki, Y | 1 |
| Gould, IM; Hobson, RP; MacKenzie, FM | 1 |
| Knapp, CC; Ludwig, MD; Pohlman, JK; Washington, JA | 1 |
| Beauchamp, D; Bergeron, MG; Morin, NJ; Simard, M; Turcotte, A | 1 |
| Ishikawa, H; Matsumoto, M; Tsubouchi, H; Tsuji, K; Yasumura, K | 1 |
| Descheemaeker, P; Goossens, H; Ieven, M; Sanders, CC; Vercauteren, E | 1 |
| Chaibi, EB; Labia, R; Scanvic, AM; Scavizzi, MR; Soilleux, MJ | 1 |
| Blahová, J; Králiková, K; Krcméry, V; Kubonová, K | 1 |
| Doern, GV; Jones, RN; Pfaller, MA; Salazar, JC | 1 |
| Barthélémy, M; Farzaneh, S; Labia, R; Péduzzi, J; Reynaud, A; Sofer, L | 1 |
| Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
| Amicosante, G; Cornaglia, G; Franceschini, N; Mazzariol, A; Perilli, M; Segatore, B; Setacci, D | 1 |
| Lister, PD; Sanders, CC; Sanders, WE | 1 |
| de Paz Arranz, S; Gómez Martínez, M; Mínguez Mena, A; Pérez Pimiento, A; Rodríguez Mosquera, M; Trampal González, A | 1 |
| Moland, ES; Sanders, CC; Thomson, KS | 1 |
| Blahová, J; Hupková, M; Králiková, K; Krcméry, V; Kubonová, K; Lísková, A | 1 |
| Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Tsetskhladze, NS; Tsuraeva, RI | 1 |
| Ho, SW; Hsueh, PR; Jan, IS; Luh, KT; Teng, LJ | 1 |
| Kinoshita, S; Kumagai, S | 1 |
| Aoki, K; Hayashi, M; Kawano, Y; Noma, T; Shikishima, Y; Yoshizawa, I | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Dembek, ZF; Gorton, TS; Mohammed, MJ; Tenover, FC | 1 |
| Inoue, M; Kuga, A; Okamoto, R | 1 |
| Hadziyannis, E; Hall, GS; Procop, GW; Thomas, L; Tuohy, M; Washington, JA | 1 |
| Cordova, Z; Somekh, E | 1 |
| Arlet, G; Donay, L; Herrmann, J; Lagrange, PH; Nadjar, D; Philippon, A; Rouveau, M; Verdet, C | 1 |
| Chalut, C; Charpentier, X; Masson, JM; Remy, MH | 1 |
| Giamarellou, H; Kavouklis, E; Kontoghiorgi, K; Voutsinas, D; Voutsinas, P | 1 |
| Canton, R; Casellas, JM; Legakis, N; Winokur, PL | 1 |
| Akasaka, S; Inatomi, H; Matsumoto, T; Muratani, T; Takahashi, K; Yamada, Y | 1 |
| de Man, P; van Belkum, A; van Pelt, C; Verbrugh, HA; Vos, MC; Wertheim, H | 1 |
| Stock, I; Wiedemann, B | 1 |
| Akasaka, S; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Takahashi, K; Yamada, Y | 1 |
| Jung, R; Messick, CR; Pendland, SL | 1 |
| Amicosante, G; Bianchi, C; De Massis, MR; Franceschini, N; Perilli, M; Rossolini, GM; Segatore, B | 1 |
| Chang, FY; Ho, M; Ishii, Y; Ma, L; Siu, LK; Yamaguchi, K | 1 |
| Fernandez, CD; Kerr, TG; Matthews, D; Midolo, PD | 1 |
| Barrett, NL; Dandekar, PK; Nicolau, DP; Nightingale, CH | 1 |
| Baize, T; Fleming, DR; Goldsmith, GH; Herzig, RH; Mudd, L; Ziegler, C | 1 |
| Jones, RN; Rhomberg, PR | 1 |
| Berezin, AG; Iakovlev, SV; Romashov, OM; Sidorenko, SV | 1 |
| Kataoka, D; Tanaka, Y | 1 |
| Alba, J; Ishiguro, M; Ishii, Y; Kimura, S; Yamaguchi, K | 1 |
| Lee, WS; Lin, ML; Liu, CY; Wang, FD | 1 |
| Chen, TP; Chen, YH; Lu, PL; Peng, CF; Tsai, JJ | 1 |
| Bonten, MJ; Florijn, A; Fluit, AC; Nijssen, S; Schmitz, FJ; Verhoef, J | 1 |
| Burgess, DS; Frei, CR | 1 |
| Jones, RN; Sader, HS | 1 |
| Cieślik, A; Gierczyński, R; Szych, J; Wardak, S | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Lyon, D; Poon, WS; Wai, S; Wong, GK | 1 |
| Arakawa, S; Deguchi, T; Egashira, T; Fujime, M; Fujita, K; Fukuhara, Y; Furuya, N; Hirakata, Y; Hirose, T; Igari, J; Imafuku, Y; Ishibashi, K; Ishihara, S; Kamidono, S; Kitamura, M; Kobayashi, Y; Kohno, S; Kondo, A; Konishi, T; Kumamoto, Y; Kumon, H; Kunishima, Y; Matsuda, J; Matsuda, S; Matsukawa, M; Matsumoto, T; Monden, K; Murai, M; Muratani, T; Naito, S; Nakano, M; Oguri, T; Oka, T; Ooe, H; Sato, S; Shigeta, S; Suzutani, T; Tsukamoto, T; Uchida, H; Watanabe, K; Yamaguchi, K; Yamaguti, O; Yoshida, H | 1 |
| Cogo, LL; Dalla Costa, LM; de Oliveira, S; de Souza, HA; do Nascimento, AJ; Higuti, IH; Matos, AP; Nogueira, Kda S; Terasawa, LB | 1 |
| Berenguer, N; Grau, S; Luque, S; Mateu-de Antonio, J | 1 |
| Das, A; Ge, Y; Talbot, GH; Thye, D | 1 |
| Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J | 1 |
| Bonnet, R; Caniça, M; Ferreira, E; Manageiro, V; Mendonça, N; Robin, F; Salgado, MJ | 1 |
| Arora, J; Dogra, A; Rao, P; Taneja, N | 1 |
| Lei, J; Lin, L; Ling, BD; Liu, G; Xie, YE; Zeng, Y | 1 |
| Ahmed, AM; Hammad, AM; Ishida, Y; Shimamoto, T | 1 |
| Bou, G; Torres, E; Villanueva, R | 1 |
| Kotsakis, SD; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Faccone, D; Galas, M; López, Y; Maggi, G; Marcano, D; Pasterán, F; Payares, D; Rapoport, M; Salgado, N; Sánchez, D; Spadola, E; Ugarte, C | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Nordmann, P; Poirel, L; Rodríguez-Martínez, JM; Ronco, E | 1 |
| Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW | 1 |
| Hsueh, PR; Ko, WC; Lu, JJ; Teng, LJ; Wang, FD; Wu, HY; Wu, JJ; Wu, TL | 1 |
| Baculik, T; Corey, GR; Friedland, D; Talbot, GH; Thye, D; Wilcox, MH | 2 |
| Corrado, ML | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Hu, F; Wang, M; Wang, P; Wang, YF; Xiong, Z; Ye, X; Zhu, D | 1 |
| Amoureux, L; Bador, J; Drabowicz, A; Duez, JM; Llanes, C; Neuwirth, C; Siebor, E | 1 |
| Drusano, GL | 1 |
| Biek, D; Eckburg, PB; Friedland, HD; Laudano, JB; Llorens, L; O'Neal, T; Rank, DR; Smith, A; Thye, D; Witherell, GW | 1 |
| Ahn, SH; Biek, D; Critchley, I; Fowler, VG; Lamlertthon, S; Llorens, L; Rude, T; Ruffin, F; Sharma-Kuinkel, BK; Tamarana, G; Tong, A; Tong, SY; Zhang, Y | 1 |
| Antunes, NT; Frase, H; Lamoureaux, TL; Vakulenko, SB | 1 |
| Giuliano, C; Johnson, LB; Kale-Pradhan, PB | 1 |
| Ambrose, PG; Bhavnani, SM; Craig, WA; Dudley, MN; Ferraro, MJ; Jones, RN | 1 |
| Beresford, E; Friedland, HD; Huang, X; Lodise, T | 1 |
| Bonomo, RA; June, CM; Kaitany, KC; Klinger, NV; Leonard, DA; Powers, RA; Ramey, ME | 1 |
| Bert, F; Bialek-Davenet, S; Leflon-Guibout, V; Nicolas-Chanoine, MH; Noussair, L | 1 |
| Condon, S; Ginocchio, CC; McWilliams, CS; Schwartz, RM | 1 |
| Eckmann, C | 1 |
| Bonomo, RA; Clasman, JR; June, CM; Kaitany, KC; Klinger, NV; LaFleur, JR; Leonard, DA; Mitchell, JM; Powers, RA; Szarecka, A; Taracila, MA; Wymore, T | 1 |
| Abdelhamed, AM; Bajaksouzian, S; Bonomo, RA; Foster, AN; Gatta, JA; Jacobs, MR; Nichols, WW; Papp-Wallace, KM; Testa, R; Winkler, ML | 1 |
| Airapetian, N; Ammenouche, N; Dupont, H; Friggeri, A; Levrard, M; Mahjoub, Y; Mammeri, H; Marciniak, S; Tinturier, F; Zogheib, E | 1 |
| Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
| Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
| Srinivas, NR | 1 |
| Boyd, D; Carpenter, M; Desruisseau, A; Janecko, N; Mangat, CS; Martz, SL; Mulvey, MR; Reid-Smith, RJ | 1 |
| Caruso, C; Gaeta, F; Maggioletti, M; Quaratino, D; Romano, A; Valluzzi, RL | 1 |
| Adler, AL; Elward, A; Haaland, W; Kronman, MP; Miles-Jay, A; Newland, JG; Qin, X; Weissman, SJ; Zaoutis, T; Zerr, DM; Zhou, C | 1 |
| Cicek, AC; Duzgun, AO; June, CM; Leonard, DA; Sandalli, C; Saral, A | 1 |
| Krause, KM; Nichols, WW; Pillar, CM; Shinabarger, DL; Stoneburner, A | 1 |
| Cannatelli, A; Di Pilato, V; Giani, T; Nichols, WW; Rossolini, GM; Testa, R | 1 |
| Dryden, M; Gonzalez, J; Iaconis, JP; Wilson, D; Zhang, Y | 1 |
| Baumert, P; Feihl, S; Gastmeier, P; Gebhardt, F; Gölz, H; Hamprecht, A; Kern, WV; Knobloch, J; Kola, A; Mischnik, A; Obermann, B; Peter, S; Querbach, C; Rohde, A; Seifert, H; Tacconelli, E; Willmann, M | 1 |
| Arthur, M; Ourghanlian, C; Soroka, D | 1 |
| Chesnel, L; Howland, K; Jacqueline, C | 1 |
| Alikhil, M; Allen, B; Epps, K; Kamataris, K; Phan, A; Tucker, C | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 2 |
| Arif, S; Bishawi, M; Maskarinec, SA; Milano, C; Miller, RA; Mourad, A | 1 |
| Engelhardt, M; Gonzalez-Rojas, Y; Gumenchuk, I; Hamed, KA; Ionescu, D; Jones, ME; Keech, R; Kim, C; Ninov, B; Overcash, JS; Saulay, M; Simeonov, S; Smart, JI; Waters, M | 1 |
| Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
| Årdal, C; Hudson, J; Kållberg, C; Klein, E; Laxminarayan, R; Lindbæk, M; Outterson, K; Røttingen, JA; Salvesen Blix, H | 1 |
| Cappellano, P; de Lima, AV; Lima, KO; Rocha, DADC; Sampaio, JLM; Sampaio, SCF | 1 |
| Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Nordmann, P; Ortiz de la Rosa, JM; Poirel, L; Sadek, M | 1 |
| Le Terrier, C; Nordmann, P; Poirel, L; Sadek, M | 1 |
| Ramsey, A; Rozario, C; Stern, J | 1 |
| Anstey, KM; Blumenthal, KG; Bystritsky, R; Doernberg, SB; Hilts-Horeczko, A; Le, VP; Lee, M; Li, F; Mulliken, JS; Otani, IM; Tang, M; Wang, L; Wattier, RL | 1 |
| Feng, Y; Ma, K; Wu, S; Zong, Z | 1 |
| Ghosh, AS; Jain, D; Panda, AP; Pandey, SD | 1 |
| Girlich, D; Leclercq, R; Naas, T; Nordmann, P | 1 |
| Anderson, KC; Kellogg, GE; Sarkar, A | 1 |
16 review(s) available for cephalosporin c and aztreonam
| Article | Year |
|---|---|
The febrile neutropenic patient: newer options for empirical therapy.
Topics: Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Fever; Humans; Neutropenia; Quinolones | 1990 |
Antimicrobial agents in pediatrics.
Topics: Adolescent; Adult; Age Factors; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Child; Child, Preschool; Cilastatin; Cystic Fibrosis; Humans; Imipenem; Infant; Tissue Distribution | 1989 |
Aztreonam in the management of gram-negative infections in penicillin-allergic patients: a review.
Topics: Aztreonam; Bacterial Infections; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Gram-Negative Bacteria; Humans; Molecular Structure; Penicillins | 1989 |
Immediate hypersensitivity reactions to beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Imipenem; Penicillins; Skin Tests; Thienamycins | 1987 |
Pathophysiology and management of postcesarean endomyometritis.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cephalosporins; Cesarean Section; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Endometritis; Female; Gentamicins; Humans; Moxalactam; Penicillins; Postoperative Complications; Pregnancy; Socioeconomic Factors | 1986 |
Therapeutic considerations in using combinations of newer beta-lactam antibiotics.
Topics: Amdinocillin; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Kinetics | 1986 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; Ciprofloxacin; Enoxacin; Humans; Imipenem; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Thienamycins | 1987 |
Antimicrobial therapy of bacterial sepsis in the newborn infant.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Cross Infection; Drug Therapy, Combination; Humans; Imipenem; Infant Mortality; Infant, Newborn; Penicillin Resistance; Penicillins; Sepsis; Thienamycins | 1985 |
Antibiotic monitoring in body fluids.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Biological Assay; Body Fluids; Cephalosporins; Chloramphenicol; Chromatography, Gas; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Immunoassay; Monitoring, Physiologic; Penicillins; Rifampin; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thiamphenicol; Vancomycin | 1985 |
The newer cephalosporins. Aztreonam and imipenem.
Topics: Aztreonam; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Monobactams; Thienamycins | 1995 |
Symposium on antimicrobial therapy. V. The carbapenems and monobactams.
Topics: Aztreonam; Bacterial Infections; Cephalosporins; Humans; Imipenem; Microbial Sensitivity Tests | 1993 |
Infectious complications in the immunocompromised host. The antimicrobial armamentarium.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Aminoglycosides; Amphotericin B; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Azoles; Aztreonam; Cephalosporins; Fluoroquinolones; Foscarnet; Ganciclovir; Humans; Imipenem; Immunocompromised Host; Infections; Neoplasms; Pneumonia, Pneumocystis; Vancomycin | 1993 |
[Characteristics and clinical value of extended-spectrum beta-lactamases].
Topics: Adolescent; Adult; Aged; Animals; Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Community Health Centers; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella; Middle Aged; Penicillins; Russia | 2003 |
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2013 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Direct challenges are the gold standard for most antibiotic allergy evaluations.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Child; Drug Hypersensitivity; Humans; Hypersensitivity; Penicillins | 2023 |
15 trial(s) available for cephalosporin c and aztreonam
| Article | Year |
|---|---|
Pathophysiology and management of postcesarean endomyometritis.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cephalosporins; Cesarean Section; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Endometritis; Female; Gentamicins; Humans; Moxalactam; Penicillins; Postoperative Complications; Pregnancy; Socioeconomic Factors | 1986 |
Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children.
Topics: Adolescent; Anti-Bacterial Agents; Aztreonam; Bacteremia; Cefixime; Cefotaxime; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Cost-Benefit Analysis; Drug Resistance, Multiple; Egypt; Female; Humans; Male; Monobactams; Salmonella typhi; Treatment Outcome; Typhoid Fever | 1995 |
Teicoplanin pharmacokinetics in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Aztreonam; Bone Marrow Transplantation; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Infant; Microbial Sensitivity Tests; Monobactams; Teicoplanin | 1996 |
Ceftazidime versus aztreonam in the treatment of pseudomonal chronic suppurative otitis media in children.
Topics: Adolescent; Aztreonam; Ceftazidime; Cephalosporins; Child; Child, Preschool; Chronic Disease; Follow-Up Studies; Humans; Infant; Monobactams; Otitis Media, Suppurative; Pseudomonas aeruginosa; Treatment Outcome | 2000 |
The effect of acetazolamide on the kinetics of four newer beta-lactams in the aqueous humor.
Topics: Acetazolamide; Aged; Aged, 80 and over; Aqueous Humor; Aztreonam; beta-Lactams; Cephalosporins; Drug Therapy, Combination; Endophthalmitis; Female; Humans; Male; Middle Aged | 2001 |
Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Aztreonam; Cefepime; Cephalosporins; Clavulanic Acid; Costs and Cost Analysis; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Ticarcillin | 2003 |
Cefepime vs. Ampicillin/Sulbactam and Aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Antibiotic Prophylaxis; Aztreonam; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Combinations; Female; Humans; Infections; Male; Middle Aged; Monobactams; Neurosurgical Procedures; Penicillins; Postoperative Complications; Prospective Studies; Treatment Outcome; Ventriculoperitoneal Shunt | 2006 |
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin Resistance; Middle Aged; Recurrence; Skin Diseases, Infectious; Streptococcus agalactiae; Treatment Outcome; Vancomycin | 2007 |
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2012 |
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vancomycin; Young Adult | 2016 |
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2021 |
171 other study(ies) available for cephalosporin c and aztreonam
| Article | Year |
|---|---|
Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
Topics: Amdinocillin; Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Daptomycin; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Peptides; Piperacillin; Vancomycin | 1992 |
[Mechanical and antibiotic preparation and infections in colorectal surgery. Comparison of 2 methods of orthograde lavage].
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Clindamycin; Colectomy; Colon; Colostomy; Female; Humans; Male; Middle Aged; Premedication; Rectum; Surgical Wound Infection; Therapeutic Irrigation | 1992 |
Comparative in vitro activity of cefepime and four extended-spectrum beta-lactams on 1,251 aminoglycoside-resistant gram-negative hospital strains.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefotaxime; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Microbial Sensitivity Tests; Species Specificity | 1992 |
Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
Topics: Amikacin; Aztreonam; Cefepime; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Half-Life; Humans; In Vitro Techniques; Pseudomonas Infections | 1992 |
Peptides related to the carboxyl terminus of human platelet factor IV with antibacterial activity.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cefepime; Cephalosporins; Drug Design; Drug Therapy, Combination; Escherichia coli; Humans; Klebsiella pneumoniae; Mice; Molecular Sequence Data; Neutropenia; Peptide Fragments; Platelet Factor 4; Protein Conformation; Pseudomonas aeruginosa; Structure-Activity Relationship | 1992 |
The incidence and beta-lactam resistance of Proteus vulgaris in hospital infections: the last decade.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Aztreonam; Bacteremia; beta-Lactamases; Cephalosporins; Cross Infection; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Moxalactam; Penicillins; Phenotype; Proteus Infections; Proteus vulgaris; Spain; Urinary Tract Infections | 1991 |
Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam.
Topics: Aztreonam; beta-Lactamases; Binding Sites; Cephalosporins; Escherichia coli; Hydrolysis; Kinetics; Lysine; Models, Molecular; Molecular Conformation; Mutagenesis, Site-Directed; Protein Conformation; Serine; Substrate Specificity | 1991 |
[Recommendations for the indication-justified use of antibiotics. 1. beta-lactam antibiotics].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; Cephalosporins; Cilastatin; Drug Combinations; Drug Resistance, Microbial; Humans; Imipenem; Penicillin Resistance | 1991 |
In-vitro and in-vivo antimicrobial activities of a novel cephalosporin derivative, CP6162, possessing a dihydroxypyridone moiety at the C-3 side chain.
Topics: Animals; Aztreonam; beta-Lactamases; Cefoperazone; Ceftazidime; Cephalosporins; Drug Evaluation, Preclinical; Evaluation Studies as Topic; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Mice, Inbred ICR; Rats; Rats, Inbred Strains | 1991 |
The effect of amphotericin B, aztreonam, imipenem and cephalosporins on the bone marrow progenitor cell activity.
Topics: Amphotericin B; Animals; Aztreonam; Bone Marrow Cells; Cephalosporins; Colony-Forming Units Assay; Evaluation Studies as Topic; Female; Humans; Imipenem; Mice; Mice, Inbred C57BL; Stem Cells | 1991 |
Chromosomally-mediated beta-lactamases produced by Levinea amalonatica with activity against methoxyimino-cephalosporins.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Species Specificity | 1991 |
Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.
Topics: Amdinocillin; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporinase; Cephalosporins; Citrobacter; Drug Synergism; Enzyme Induction; Escherichia coli; Gram-Negative Bacteria; Hydrolysis; Penicillinase; Proteus vulgaris; Pseudomonas aeruginosa | 1990 |
In vitro antimicrobial activity of a novel aminothiazolylglycylcephalosporin, MT0703S, compared with that of ceftazidime, cefoperazone and aztreonam.
Topics: Aztreonam; beta-Lactamases; Cefoperazone; Ceftazidime; Cephalosporins; Drug Interactions; Escherichia coli; Iron; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus | 1990 |
Monotherapy for empirical management of febrile neutropenic patients.
Topics: Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Costs and Cost Analysis; Fever; Humans; Imipenem; Infections; Neutropenia; Quinolones | 1990 |
[Antibacterial activity of carumonam and cefpirome on hospital strains resistant to gentamicin and cephalothin: comparison with other beta-lactam antibiotics, new fluoroquinolones, aminoglycosides and other antibiotics].
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cefpirome; Cephalosporins; Cephalothin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Gentamicins; Gram-Negative Bacteria; In Vitro Techniques; Quinolones | 1990 |
Immunogenicity and cross-allergenicity of aztreonam.
Topics: Aztreonam; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Penicillins | 1990 |
L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.
Topics: Aerobiosis; Anaerobiosis; Aztreonam; Bacteria; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Hydrolysis; Isoindoles; Microbial Sensitivity Tests; Molecular Structure; Piperacillin; Pseudomonas aeruginosa; Structure-Activity Relationship | 1989 |
Investigation into the immunologic cross-reactivity of aztreonam with other beta-lactam antibiotics.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibody Affinity; Antibody Formation; Aztreonam; Benzeneacetamides; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Epitopes; Female; Humans; Immune Sera; Immunoglobulin E; Immunoglobulin G; Male; Middle Aged; Penicillanic Acid; Penicillins; Polylysine; Radioimmunoassay; Skin Tests | 1985 |
[Activity of 9 beta-lactam antibiotics combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Citrobacter; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Drug Synergism; Enterobacter; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Klebsiella; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 1988 |
In vitro activity of BRL 36650, a new penicillin.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas; Pseudomonas aeruginosa | 1986 |
[Susceptibility of clinically isolated strains to aztreonam].
Topics: Aztreonam; Bacterial Infections; Cephalosporins; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1988 |
Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam.
Topics: Aztreonam; beta-Lactamases; Cephalosporins; Drug Resistance, Microbial; France; Klebsiella pneumoniae | 1988 |
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.
Topics: Anti-Bacterial Agents; Aztreonam; Cefpirome; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Leucomycins; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1985 |
[Third generation cephalosporins, monobactams and carbapenems].
Topics: Aztreonam; Bacteria; Bacterial Infections; Cefotaxime; Cephalosporins; Imipenem; Thienamycins | 1988 |
[The influence of a monobactam antibiotic, aztreonam, and other antibiotics on blood coagulation in vitamin K-deficient rats].
Topics: Ampicillin; Animals; Aztreonam; Blood Coagulation; Cecum; Cephalosporins; Colony Count, Microbial; Dose-Response Relationship, Drug; Hypoprothrombinemias; Injections, Intraperitoneal; Male; Rats; Rats, Inbred Strains | 1988 |
Beta-lactam resistance in Aeromonas spp. caused by inducible beta-lactamases active against penicillins, cephalosporins, and carbapenems.
Topics: Aeromonas; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Outer Membrane Proteins; beta-Lactamases; Cephalosporins; Drug Resistance, Microbial; Enzyme Induction; Humans; Imipenem; Isoelectric Focusing; Male; Penicillins | 1988 |
A survey of the kinetic parameters of class C beta-lactamases. Cephalosporins and other beta-lactam compounds.
Topics: Aztreonam; beta-Lactamases; Cephalosporins; Hydrolysis; Imipenem; Kinetics; Moxalactam; Substrate Specificity | 1988 |
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles.
Topics: Aztreonam; Cefamandole; Cefonicid; Cefoperazone; Cefuroxime; Cephalosporins; Clindamycin; Drug Combinations; Drug Incompatibility; Drug Packaging; Drug Stability; Syringes | 1988 |
Antibiotic choices for the penicillin-allergic patient.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Gram-Negative Bacteria; Humans; Penicillins; Skin Tests | 1988 |
New trends in paediatric antibiotic therapy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Child; Humans; Pediatrics; Penicillins | 1987 |
Nosocomial and nursing home-acquired pneumonia. Recent therapeutic advances.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Cilastatin; Clavulanic Acid; Clavulanic Acids; Cross Infection; Cyclopropanes; Humans; Imipenem; Nursing Homes; Pneumonia; Thienamycins; Ticarcillin | 1987 |
Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin.
Topics: Aztreonam; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbenicillin; Cefotaxime; Ceftazidime; Cephalosporins; Gentamicins; Humans; Imipenem; Microbial Sensitivity Tests; Penicillin Resistance; Thienamycins | 1986 |
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Citrobacter; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Pseudomonas | 1986 |
Modulation of bacteriolysis by cooperative effects of penicillin-binding proteins 1a and 3 in Escherichia coli.
Topics: Acyltransferases; Aztreonam; Bacterial Proteins; Bacteriolysis; Carrier Proteins; Cefsulodin; Cephalosporins; Escherichia coli; Hexosyltransferases; Multienzyme Complexes; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases | 1986 |
Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography.
Topics: Aztreonam; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Penicillins | 1987 |
Comparative in-vitro activity of cefodizime, cefpirome, carumonam and RU-28965 with other antimicrobials against anaerobes.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria, Anaerobic; Cefotaxime; Cefpirome; Cephalosporins; Leucomycins; Microbial Sensitivity Tests | 1987 |
In vitro activity of the two new oral cephalosporins RO 15-8074 and RO 19-5247.
Topics: Aztreonam; Cefmenoxime; Ceftizoxime; Cephalexin; Cephalosporins; Cephradine; Enterobacteriaceae; Pseudomonas | 1987 |
In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.
Topics: Aztreonam; Blood-Brain Barrier; Brucella; Brucellosis; Cephalosporins; Humans; Microbial Sensitivity Tests | 1986 |
Comparative in vitro activity of aztreonam and other antimicrobial agents against Salmonella species.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Humans; Microbial Sensitivity Tests; Salmonella; Seawater | 1985 |
Comparative activity of the penem antibiotic Sch 34343 against gram-negative and gram-positive bacteria with special reference to multiresistant strains.
Topics: Anti-Bacterial Agents; Aztreonam; Cefamandole; Cephalosporins; Corynebacterium; Gram-Negative Bacteria; Gram-Positive Bacteria; Lactams; Methicillin; Microbial Sensitivity Tests; Penicillin Resistance; Staphylococcus | 1985 |
Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae.
Topics: Ampicillin; Animals; Aztreonam; beta-Lactamases; Cefuroxime; Cephalosporins; Extracellular Space; Female; Fibrin; Haemophilus Infections; Haemophilus influenzae; Microbial Sensitivity Tests; Rabbits | 1985 |
The in vitro activity of the newer beta-lactam antibiotics against 124 strains of gram-negative bacilli.
Topics: Anti-Bacterial Agents; Azlocillin; Aztreonam; Cephalosporins; Enterobacteriaceae; Gentamicins; Imipenem; Microbial Sensitivity Tests; Moxalactam; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Ticarcillin | 1985 |
Comparative in vitro activity of cefodizime, ceftazidime, aztreonam, and other selected antimicrobial agents against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Aztreonam; Cefotaxime; Ceftazidime; Cephalosporins; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1983 |
Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.
Topics: Acinetobacter; Alcaligenes; Anti-Bacterial Agents; Aztreonam; Bordetella; Cefamandole; Cefotaxime; Cefoxitin; Cefsulodin; Ceftazidime; Ceftriaxone; Cephalosporins; Cephalothin; Drug Resistance, Microbial; Flavobacterium; Gram-Negative Aerobic Bacteria; Moraxella; Pseudomonas | 1983 |
Lack of interference of five new beta-lactam antibiotics with serum creatinine determination.
Topics: Anti-Bacterial Agents; Autoanalysis; Aztreonam; Cefoperazone; Cefotaxime; Ceftazidime; Ceftizoxime; Ceftriaxone; Cephalosporins; Creatinine; Humans; Male | 1983 |
Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chloramphenicol; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1984 |
Therapeutic activity of ceftazidime and eleven other beta-lactam antibiotics against experimental Haemophilus influenzae, type b meningitis.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Cephalosporins; Haemophilus influenzae; Meningitis, Haemophilus; Rats | 1984 |
The morphological response of Pseudomonas aeruginosa to azthreonam, cefoperazone, ceftazidime and N-formimidoyl thienamycin.
Topics: Anti-Bacterial Agents; Aztreonam; Cefoperazone; Ceftazidime; Cephalosporins; Imipenem; Microbial Sensitivity Tests; Microscopy, Electron; Nephelometry and Turbidimetry; Pseudomonas aeruginosa; Spheroplasts; Thienamycins | 1984 |
[Comparative in vitro activity of 5 beta-lactams (cefoperazone, cefsulodin, ceftazidime, azthreonam, N-formimidoyl-thienamycin) on 90 strains of Pseudomonas aeruginosa with various levels of resistance to ticarcillin].
Topics: Anti-Bacterial Agents; Aztreonam; Cefoperazone; Cefsulodin; Ceftazidime; Cephalosporins; Imipenem; Penicillin Resistance; Penicillins; Pseudomonas aeruginosa; Thienamycins; Ticarcillin | 1984 |
In-vitro susceptibility of salmonellae to antimicrobial agents.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Feces; Humans; Microbial Sensitivity Tests; Peru; Salmonella; Salmonella typhi | 1984 |
Trends in the development of beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cephalosporins; Humans; Imipenem; Penicillins; Technology, Pharmaceutical; Thienamycins | 1984 |
Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Microbial Sensitivity Tests | 1983 |
Antibacterial activity of a monocyclic beta-lactam SQ 26,776.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; beta-Lactamases; beta-Lactams; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Pseudomonas aeruginosa | 1981 |
Bactericidal activity of SQ 26776.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Lactams; Pseudomonas aeruginosa | 1981 |
Comparative in vitro study of SQ26,776.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Dose-Response Relationship, Drug; Humans; Lactams; Penicillin Resistance; Penicillins | 1982 |
Extended-spectrum beta-lactamases conferring resistance to monobactams and oxyimino-cephalosporins in clinical isolates of Serratia marcescens.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ceftriaxone; Cephalosporins; Humans; Isoelectric Focusing; Monobactams; Plasmids; Serratia marcescens | 1995 |
Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Topics: Aztreonam; Cefepime; Cefotaxime; Cefpirome; Ceftazidime; Ceftizoxime; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Microbial Sensitivity Tests; Sensitivity and Specificity | 1995 |
TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis.
Topics: Aztreonam; beta-Lactamases; Binding Sites; Catalysis; Cefotaxime; Ceftazidime; Cefuroxime; Cephalosporins; Escherichia coli; Hydrolysis; Kinetics; Mutation; Penicillins; Plasmids; Stereoisomerism; Substrate Specificity | 1994 |
In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Doxycycline; Enterobacter cloacae; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Korea; Penicillins; Pseudomonas aeruginosa; Serratia marcescens | 1993 |
Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; DNA Probes; DNA, Bacterial; Humans; Isoelectric Focusing; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Phenotype; Plasmids | 1993 |
Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chile; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Synergism; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Indicators and Reagents; Microbial Sensitivity Tests | 1993 |
Klebsiella pneumoniae infections in Greek hospitals. Dissemination of plasmids encoding an SHV-5 type beta-lactamase.
Topics: Aztreonam; Bacteriophage Typing; beta-Lactamases; Ceftazidime; Cephalosporins; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Greece; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Monobactams; Plasmids | 1995 |
In vitro antibacterial properties of T-5575 and T-5578 novel parenteral 2-carboxypenams.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carrier Proteins; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Hexosyltransferases; Humans; Lactams; Microbial Sensitivity Tests; Monobactams; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding | 1995 |
Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Monobactams; Penicillins; Piperacillin | 1996 |
[Variation in transfer resistance to cefotaxime, ceftazidime and aztreonam in strains of Acinetobacter sp., Enterobacter sp. and Citrobacter sp. isolated from the same university hospitals].
Topics: Acinetobacter; Aztreonam; Cefotaxime; Ceftazidime; Cephalosporins; Citrobacter; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Enterobacter; Hospitals, University; Humans; Monobactams; R Factors | 1996 |
[Acute bacterial parotitis caused by Serratia marcescens].
Topics: Acute Disease; Aztreonam; Cefotaxime; Cephalosporins; Child; Diagnosis, Differential; Female; Humans; Middle Aged; Monobactams; Parotitis; Serratia Infections; Serratia marcescens; Time Factors; Tomography, X-Ray Computed | 1996 |
Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime.
Topics: Amino Acid Sequence; Aztreonam; beta-Lactamases; Ceftazidime; Cephalosporins; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Mutagenesis, Site-Directed; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 1996 |
[Antibacterial activities of combination uses of cefpirome with various antibiotics in vitro against clinically isolated glucose non-fermentative gram-negative rods: part 1. the results against Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefpirome; Cephalosporins; Drug Combinations; Drug Synergism; Gentamicins; Imipenem; Piperacillin; Pseudomonas aeruginosa; Tobramycin | 1996 |
An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Cefotaxime; Ceftazidime; Cefuroxime; Cephalosporins; Ciprofloxacin; Costs and Cost Analysis; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Gentamicins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Scotland | 1996 |
Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens; Tazobactam; Ticarcillin; Time Factors | 1996 |
Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.
Topics: Animals; Aztreonam; Ceftazidime; Cephalosporins; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Fibrin; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia Infections; Serratia marcescens | 1997 |
Synthesis and structure-activity relationships of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' or C-7 catechol or related aromatics.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Catechols; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Structure-Activity Relationship | 1996 |
Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.
Topics: Aztreonam; beta-Lactamases; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; False Positive Reactions; Klebsiella; Microbial Sensitivity Tests; Monobactams; Sensitivity and Specificity | 1997 |
TEM-8: a paradoxical ceftazidimase that owes its uniqueness to the presence of serine residues at positions 164 and 238.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporins; Escherichia coli; Penicillin G | 1997 |
Transferable resistance to cefotaxime, ceftazidime, and aztreonam and production of extended-spectrum beta-lactamase in a strain of Salmonella enteritidis.
Topics: Aztreonam; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple; Humans; Infant; Monobactams; Plasmids; Salmonella enteritidis; Transformation, Bacterial | 1997 |
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; Cefepime; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporinase; Cephalosporins; Cohort Studies; Colombia; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Reproducibility of Results; Staphylococcus; Sulbactam | 1997 |
Characterization and amino acid sequence of the OXY-2 group beta-lactamase of pI 5.7 isolated from aztreonam-resistant Klebsiella oxytoca strain HB60.
Topics: Amino Acid Sequence; Aztreonam; beta-Lactamases; Cephalosporins; Drug Resistance, Microbial; Klebsiella; Molecular Sequence Data; Monobactams; Penicillins; Sequence Homology, Amino Acid | 1997 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Clavulanic Acid; Drug Interactions; Drug Resistance, Multiple; Enzyme Inhibitors; Isoelectric Focusing; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Penicillanic Acid; Providencia; Sulbactam; Tazobactam | 1998 |
Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.
Topics: Aztreonam; Cefepime; Cephalosporinase; Cephalosporins; Drug Therapy, Combination; Microbial Sensitivity Tests; Monobactams; Mutation; Pseudomonas aeruginosa | 1998 |
Aztreonam and ceftazidime: evidence of in vivo cross allergenicity.
Topics: Aztreonam; Ceftazidime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Male; Middle Aged; Monobactams; Patch Tests; Respiratory Tract Infections; Skin Tests | 1998 |
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Escherichia coli; Escherichia coli Infections; False Negative Reactions; False Positive Reactions; Humans; Klebsiella; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Reproducibility of Results | 1998 |
Transfer of resistance to oxy-imino-cephalosporins and of extended-spectrum beta-lactamase productions in Klebsiella pneumoniae strains from infected neonates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Conjugation, Genetic; Drug Resistance, Multiple; Escherichia coli; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Proteus mirabilis | 1998 |
[Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe].
Topics: Aminoglycosides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antigens, Bacterial; Aztreonam; Bacterial Proteins; Cephalosporins; Disease Models, Animal; Doxycycline; Fluoroquinolones; Mice; Monobactams; Penicillins; Phenotype; Plague; Rifampin | 1998 |
Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics.
Topics: Anti-Infective Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Ciprofloxacin; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Ofloxacin; Thienamycins | 1998 |
[Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Meropenem; Monobactams; Norfloxacin; Tetracycline; Thienamycins | 1998 |
A comparative investigation of the restorative effects of roxithromycin on neutrophil activities.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Blood Bactericidal Activity; Cefaclor; Cephalosporins; Child; Disabled Persons; Drug Interactions; Female; Flow Cytometry; Humans; Hydrogen Peroxide; Macrophage-1 Antigen; Male; Monobactams; Neutrophils; Ofloxacin; Phagocytosis; Roxithromycin | 1998 |
Multicenter survey of the in vitro activity of four expanded-spectrum beta-lactams against consecutive contemporary clinical isolates.
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; beta-Lactams; Cefotaxime; Cefpodoxime; Ceftazidime; Ceftizoxime; Cephalosporins; Microbial Sensitivity Tests; Monobactams | 1998 |
Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut.
Topics: Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Centers for Disease Control and Prevention, U.S.; Cephalosporin Resistance; Cephalosporins; Connecticut; Escherichia coli; Humans; Klebsiella pneumoniae; Laboratories; Microbial Sensitivity Tests; United States | 1999 |
ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae.
Topics: Amino Acid Sequence; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Cephalosporins; DNA, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Mutation; Plasmids; Sequence Analysis, DNA | 2000 |
Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Clavulanic Acid; Escherichia coli; Humans; Klebsiella; Klebsiella pneumoniae; Microbial Sensitivity Tests; Phenotype | 2000 |
Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei.
Topics: Amino Acid Sequence; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Cefepime; Cefotaxime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Cephamycins; Cloning, Molecular; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Electrophoresis, Gel, Pulsed-Field; France; Hafnia; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Plasmids; Polymerase Chain Reaction | 2000 |
Differential responses of Escherichia coli cells expressing cytoplasmic domain mutants of penicillin-binding protein 1b after impairment of penicillin-binding proteins 1a and 3.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; Carrier Proteins; Cephaloridine; Cephalosporins; Cytoplasm; Dimerization; Escherichia coli; Escherichia coli Proteins; Hexosyltransferases; Isoenzymes; Molecular Sequence Data; Multienzyme Complexes; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Serine-Type D-Ala-D-Ala Carboxypeptidase | 2001 |
Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.
Topics: Asia, Eastern; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Escherichia coli; Europe; Klebsiella pneumoniae; Latin America; Microbial Sensitivity Tests; North America; Phenotype; Proteus mirabilis; Ribotyping; Salmonella | 2001 |
Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce beta-lactamase.
Topics: Adult; Anti-Infective Agents; Aztreonam; Cefdinir; Ceftriaxone; Cephalosporins; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Gonorrhea; Humans; Japan; Male; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Neisseria gonorrhoeae; Roxithromycin; Spectinomycin; Urethritis | 2001 |
Improved detection of methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and ceftizoxime.
Topics: Aztreonam; Bacteriological Techniques; Ceftizoxime; Cephalosporins; Culture Media; Humans; Mannitol; Methicillin Resistance; Monobactams; Phenolsulfonphthalein; Staphylococcal Infections; Staphylococcus aureus | 2001 |
beta-Lactam-susceptibility patterns of Plesiomonas shigelloides strains: importance of inoculum and medium.
Topics: Animals; Aztreonam; beta-Lactams; Carbapenems; Cephalosporins; Culture Media; Dogs; Humans; Microbial Sensitivity Tests; Penicillins; Plesiomonas | 2001 |
Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Cefozopran; Cephalosporins; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Female; Gonorrhea; Humans; Japan; Male; Microbial Sensitivity Tests; Monobactams; Neisseria gonorrhoeae; Penicillins; Polymorphism, Restriction Fragment Length | 2001 |
In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Synergism; Humans; Lactams; Levofloxacin; Microbial Sensitivity Tests; Monobactams; Ofloxacin; Penicillins; Piperacillin; Pseudomonas aeruginosa | 2002 |
Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey.
Topics: Aztreonam; beta-Lactamases; Cephalosporins; Escherichia coli; Humans; Italy; Kinetics; Molecular Sequence Data; Monobactams; Proteus Infections; Proteus mirabilis; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum beta-lactamase isolated from Escherichia coli.
Topics: Amino Acid Substitution; Aztreonam; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Escherichia coli; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Monobactams; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial; Taiwan | 2002 |
Detection of extended spectrum beta-lactamases in the routine clinical microbiology laboratory.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Child; Drug Resistance, Bacterial; False Positive Reactions; Gram-Negative Bacteria; Humans; Microbiological Techniques | 2002 |
Utilization of extended-spectrum beta-lactamase (ESBL) detection systems in microbiology laboratories: survey of Connecticut hospitals from 1998-2002.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Connecticut; Escherichia coli; Humans; Klebsiella pneumoniae; Laboratories; Microbial Sensitivity Tests; United States | 2003 |
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
Topics: Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Female; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; North America; Sensitivity and Specificity; Thienamycins; Tobramycin | 2003 |
The combination of aztreonam and cefozopran against Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; Cefozopran; Cephalosporins; Humans; Microbial Sensitivity Tests; Stenotrophomonas maltophilia | 2004 |
Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis.
Topics: Aztreonam; beta-Lactamases; Ceftazidime; Cephalosporins; Escherichia coli; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Monobactams; Mutagenesis, Site-Directed; Mutation | 2004 |
In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
Topics: Acinetobacter baumannii; Ampicillin; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Enterobacter cloacae; Enzyme Inhibitors; Gram-Negative Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Serratia marcescens; Sulbactam | 2004 |
In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Taiwan | 2004 |
Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Humans; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests | 2004 |
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Intensive Care Units; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; United States | 2005 |
Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.
Topics: Acinetobacter; Ampicillin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sulbactam | 2005 |
[The occurrence and characterisation of oxy-imino-beta-lactams resistant strains among Salmonella enterica subsp. enterica isolated in Poland].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Drug Resistance, Multiple, Bacterial; Poland; Salmonella enterica | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Topics: Aminoglycosides; Ampicillin; Anti-Infective Agents; Aztreonam; Cefixime; Cefozopran; Cefpirome; Cefpodoxime; Ceftizoxime; Cephalosporins; Dibekacin; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Proteus mirabilis; Pseudomonas aeruginosa; Quinolones; Serratia marcescens; Staphylococcus aureus; Thienamycins; Urinary Tract Infections; Vancomycin | 2006 |
Occurrence of extended-spectrum beta-lactamases in Enterobacteriaceae isolated from hospitalized patients in Curitiba, southern Brazil.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Brazil; Cephalosporins; Clavulanic Acid; Enterobacteriaceae; Hospitals, University; Humans; Microbial Sensitivity Tests | 2006 |
[Cefepime and aztreonam shortages: we've run out of ammo].
Topics: Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Health Planning; Spain | 2007 |
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam | 2007 |
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Arginine; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Computer Simulation; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Lysine; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Penicillins; Protein Conformation; Protein Structure, Tertiary | 2008 |
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Humans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Urinary Tract Infections | 2008 |
Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Enterobacter cloacae from a Teaching Hospital in China.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; China; Conjugation, Genetic; Enterobacter cloacae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Sequence Analysis, DNA | 2008 |
First characterization and emergence of SHV-60 in raw milk of a healthy cow in Japan.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cattle; Cephalosporins; Drug Resistance, Bacterial; Female; Japan; Klebsiella pneumoniae; Lactation; Mastitis, Bovine; Microbial Sensitivity Tests; Milk; Molecular Sequence Data; Public Health | 2008 |
Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Automation; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Genetic Predisposition to Disease; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Protein Binding; Protein Structure, Secondary | 2009 |
First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Child; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Quinolones; Thienamycins; Urine; Venezuela | 2008 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporin Resistance; Cephalosporinase; Cephalosporins; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Mutagenesis, Site-Directed | 2010 |
Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Guideline Adherence; Laboratories; Microbial Sensitivity Tests; Taiwan | 2010 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Proteus mirabilis | 2011 |
First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.
Topics: Achromobacter denitrificans; Aztreonam; Bacterial Outer Membrane Proteins; Cephalosporins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Nalidixic Acid | 2011 |
Early endpoints for acute bacterial skin and skin structure infections.
Topics: Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2012 |
Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.
Topics: Age Factors; Aztreonam; Bacterial Toxins; Ceftaroline; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Exotoxins; Female; Genotype; Humans; Leukocidins; Male; Methicillin-Resistant Staphylococcus aureus; Polymerase Chain Reaction; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2012 |
Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6.
Topics: Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Biocatalysis; Carbapenems; Cephalosporins; Escherichia coli; Hydrolysis; Isoenzymes; Kinetics; Microbial Sensitivity Tests; Penicillins; Substrate Specificity | 2012 |
Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Community-Acquired Infections; Endpoint Determination; Humans; Pneumonia; Randomized Controlled Trials as Topic; Retrospective Studies; Soft Tissue Infections; Time Factors; Treatment Outcome; Vancomycin | 2012 |
Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Costs and Cost Analysis; Drug Therapy, Combination; Economics, Hospital; Formularies, Hospital as Topic; Humans; Length of Stay; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2013 |
Structures of the class D Carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam.
Topics: Acinetobacter; Amino Acid Sequence; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Crystallography, X-Ray; Doripenem; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid | 2013 |
Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Humans; Microbial Sensitivity Tests | 2014 |
Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Humans; Incidence; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2014 |
[Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
Topics: Aztreonam; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
Structural basis of activity against aztreonam and extended spectrum cephalosporins for two carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Aztreonam; Bacterial Proteins; beta-Lactamases; Cephalosporins; Hydrolysis; Kinetics; Protein Structure, Secondary | 2015 |
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ceftaroline; Ceftazidime; Cephalosporins; Escherichia coli; Humans; Microbial Sensitivity Tests | 2015 |
Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pilot Projects; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2015 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Synergism; Enterobacteriaceae; Escherichia coli Proteins; Gene Expression; Lactams; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Piperacillin; Plasmids; Protein Isoforms; Thienamycins | 2016 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine,
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Doripenem; Feces; Fluoroquinolones; Heterocyclic Compounds, 3-Ring; Humans; Imipenem; Linezolid; Naphthyridines; Oxazines; Oxolinic Acid; Pefloxacin; Piperazines; Pyridones; Retrospective Studies; Rifampin | 2016 |
Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.
Topics: Amino Acid Sequence; Animals; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Canada; Carbapenems; Cephalosporins; Clavulanic Acid; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Penaeidae; Penicillanic Acid; Penicillins; Seafood; Sequence Alignment; Sequence Analysis, DNA; Tazobactam; Vibrio cholerae | 2016 |
Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins.
Topics: Adolescent; Adult; Aged; Aztreonam; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immune Tolerance; Immunoglobulin E; Male; Middle Aged; Patch Tests; Penicillins; Phenotype; Skin Tests; T-Lymphocytes; Young Adult | 2016 |
Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cefotaxime; Ceftazidime; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Prospective Studies; Young Adult | 2016 |
Kinetic characterization of GES-22 β-lactamase harboring the M169L clinical mutation.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Clavulanic Acid; Drug Resistance, Bacterial; Hydrolysis; Mutation; Penicillins; Plasmids; Protein Conformation; Substrate Specificity; Turkey | 2016 |
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sulbactam | 2016 |
Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Escherichia coli; Gene Expression; Humans; Microbial Sensitivity Tests | 2016 |
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Cephalosporin Resistance; Cephalosporins; Clavulanic Acid; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Germany; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2017 |
Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Topics: Amino Acid Motifs; Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Clavulanic Acid; Cloning, Molecular; Drug Combinations; Escherichia coli; Gene Expression; Kinetics; Mutation; Recombinant Proteins; Reverse Genetics; Substrate Specificity | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
Initiative to reduce aztreonam use in patients with self-reported penicillin allergy: Effects on clinical outcomes and antibiotic prescribing patterns.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Cephalosporins; Drug Hypersensitivity; Drug Prescriptions; Female; Humans; Male; Middle Aged; Penicillins; Pharmacists; Retrospective Studies; Self Report; Treatment Outcome | 2018 |
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Surgical infection prophylaxis prior to left ventricular assist device implantation: A survey of clinical practice.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aztreonam; Cephalosporins; Cross-Sectional Studies; Drug Therapy, Combination; Fluconazole; Heart-Assist Devices; Humans; Levofloxacin; Prosthesis Implantation; Prosthesis-Related Infections; Rifampin; Surgical Wound Infection; Surveys and Questionnaires; Vancomycin | 2020 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Clavulanic Acids; Drug Synergism; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2021 |
The effect of generic market entry on antibiotic prescriptions in the United States.
Topics: Anti-Bacterial Agents; Aztreonam; Cefdinir; Cefprozil; Cephalosporins; Costs and Cost Analysis; Databases, Pharmaceutical; Drug Costs; Drug Industry; Drug Prescriptions; Drugs, Generic; Humans; United States | 2021 |
A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Ceftazidime; Cephalosporins; Klebsiella pneumoniae | 2022 |
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Escherichia coli Infections; Humans; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Microbial Sensitivity Tests | 2023 |
Impact of an Inpatient Allergy Guideline on β-Lactam and Alternative Antibiotic Use.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cephalosporins; Drug Hypersensitivity; Humans; Hypersensitivity; Inpatients; Penicillins; Retrospective Studies | 2023 |
Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacter; Humans; Microbial Sensitivity Tests; Mutation | 2023 |
The MSMEG_1586 of M. smegmatis Is a Penicillin-Interactive Enzyme That Can Potentially Hydrolyse Aztreonam and Cephalosporins.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carboxypeptidases; Cephalosporins; Escherichia coli; Penicillins | 2023 |
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
Topics: Amino Acid Sequence; Bacillus; Bacterial Proteins; beta-Lactamases; Chromosome Mapping; Chromosomes, Bacterial; Cloning, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Sequence Homology, Amino Acid; Substrate Specificity | 2007 |
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics | 2012 |